Please use this identifier to cite or link to this item:
|Title:||Effectiveness of monopolar dielectric transmission of pulsed electromagnetic for multiple sclerosis-related pain: A pilot study|
Ibanez-Vera, A. J.
|metadata.dc.contributor.authoraffiliation:||[Hochsprung, A.] Hosp Virgen de la Macarena, Unidad EM, Serv Neurofisioterapia, Seville, Spain|
[Escudero-Uribe, S.] Hosp Virgen de la Macarena, Unidad EM, Serv Neurofisioterapia, Seville, Spain
[Ibanez-Vera, A. J.] Univ Jaen, Dept Ciencias Salud, Area Fisioterapia, Jaen, Spain
[Izquierdo-Ayuso, G.] Hosp Virgen de la Macarena, Unidad EM, Seville, Spain
|Keywords:||Multiple sclerosis;Pain;Electrotherapy;Radiofrequency;Neuropathic pain;Trigeminal neuralgia;Electrical nerve-stimulation;Quality-of-life;Low-back-pain;Biological tissues;Spanish version;Efficacy;Management;Mechanisms;Frequency;Fatigue|
|Publisher:||Elsevier espana slu|
|Abstract:||Introduction: Pain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methods: This study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.Results: Statistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.Conclusions: Treatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. (C) 2018 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.|
|Appears in Collections:||Producción 2020|
Files in This Item:
There are no files associated with this item.
This item is protected by original copyright
This item is licensed under a Creative Commons License